Zuellig Pharma and Vifor Consumer Health, a Galenica Group company based in Switzerland, have recently stepped up their relationship, signing a regional licensing deal that will see Zuellig Pharma take responsibility for the import, distribution, marketing and sale of Perskindol across Asia.

Perskindol is a topical painkiller that helps to alleviate pain and promote the healing process in cases of general body pain, muscle cramps, tension, strains, bruises and sprains.

Zuellig Pharma Senior Vice President Commercial Solutions George Eassey said: “Perskindol is a fantastic brand with huge potential across Asia. It is already recognized by orthopedists, athletes and consumers as an excellent solution for body pain in the markets where it is present and we have no doubt that we will be able to build on this success in other parts of the region.” Zuellig Pharma has been promoting Perskindol in Thailand and Malaysia for more than a decade.

“The sales and promotion activity carried out by our teams in these countries has driven strong double digit growth for the brand. This new regional licensing deal will allow us to accelerate this momentum,” added Mr Eassey.

Vifor Consumer Health Head of Global Brands Michele Borri said: “We are delighted to have Zuellig Pharma as our distributing partner, their long time expertise and wide presence in Asia gives us strong confidence that we will sustainably develop our iconic Swiss brand across the whole region. I have been working personally with George and his teams in the existing markets and I am amazed by their capabilities and commitment to bringing customers and consumers great solutions to their needs.”

Mr Eassey said that this new deal serves as a platform for Zuellig Pharma and Vifor Consumer Health to further build their relationship. “Vifor Consumer Health has a number of exciting brands in its portfolio. We look forward to working with the company to bring more of these products to Asia,” he concluded.